New Delhi: The country's indigenous vaccine 'Covaxin' may soon get WHO approval. In fact, Bharat Biotech, the company manufacturing covaxin in India, sent WHO to EOI Expression of Interest. It has now been accepted by the WHO, and a pre-submission meeting of The India Biotech and World Health Organization (WHO) is scheduled to be held on June 23. Let me tell you all that covaxin has been developed by ICMR and Bharat Biotech together. In this case, covaxin may now be included in the list of WHO. Covaxin is currently out of the list of WHO and due to this, the vaccine vaccinators are not able to travel to some countries.
In view of all this, this decision has been taken and this decision is a relief for those travelling abroad. Let me tell you that two vaccines are currently being administered in India, one is indigenous covaxin and the other is covishield. Recently, Bharat Biotech in a statement said, "The scientific standards and commitment of the indigenous Covid-19 vaccine covaccine covaccine developed by it are transparent, so far the company has published nine research papers on the safety and impact of vaccines".
In fact, Suchitra Ila, co-founder and joint managing director of Bharat Biotech, had tweeted and through that tweet, she said, "The scientific standards and commitment of covaxin is transparent. The academic journal, leading reviewers, NIV-ICMR-BB researchers and scientists have published nine studies and data".
In a statement, Bharat Biotech had also said, "India's regulators have closely reviewed the complete data of the trial in the first and second phases of the covaccine and the partial data of the third phase. For time-bound best review, the company has already published nine research studies in 12 months on the safety and impact of covaccine in the five globally prestigious best review journals. Covaxin is the only completely inactive corona virus-based vaccine that has published data on human trials in India".
Strong sales growth at Indian pharma Cos likely in current FY on pandemic recovery: Fitch
Strong sales growth at Indian pharma Cos likely in current FY on pandemic recovery: Fitch
